Dulaglutide Effect on Proteins Associated With CKD Progression.

McFarlin BE, Tye SC, Satake E, Md Dom ZI, Kechter A, Wilson JM, Krolewski AS, Duffin KL

Kidney international reports21 Jan 2026Cited by 1 (Europe PMC)

PMID41732754PMCIDPMC12925400DOI10.1016/j.ekir.2026.103789PepBankPUB-41732754

Summary

IntroductionIn the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine. This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk.MethodsPlasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform. Changes in circulating JKP protein concentrations from baseline to 6 months were determined.ResultsBaseline JKP protein concentrations were similar between groups. After 6 months, 14 JKP proteins increased in the insulin glargine group and decreased in the dulaglutide group with statistically significant between-group differences. The most significant differences were observed for 8 tumor necrosis factor (TNF)-receptors (TNF-R1, -R2, -R3, -R4, -R6B, -R7, -R19L, and -R27), key mediators of inflammatory and apoptotic pathways. In addition, CD160, WFDC2, DLL1, LAYN, SYND1, and EPHA2 were significantly different between treatments, although to a lesser degree, and 7 other proteins remained unaffected. Kidney injury molecule 1 (KIM1), a marker of proximal tubule stress, declined in both groups without significant differences. Treatment effects were more pronounced in participants with lower baseline estimated glomerular filtration rate or higher baseline urinary albumin-to-creatinine ratio, hemoglobin A1c, or body mass index.ConclusionSix months of dulaglutide treatment significantly lowered concentrations of 14 JKP proteins, particularly those involved in inflammatory and fibrotic pathways. These findings provide insight into biological mechanisms that may underlie the reno-protective effects of dulaglutide.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study17

16 results from studies that gave the peptide. 16 results from people.

01HumanNon-randomized trialMechanism
In participants with T2D and CKD, TNF-R1 decreased with dulaglutide and increased with insulin glargine, with a significant treatment difference.
In plain wordsIn patients with diabetes and kidney disease, TNF-R1 fell with dulaglutide and rose with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTNF-R1
Study
n = 249
Comparator
Insulin glargine
Outcome group
Inflammation markers · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
The most significant differences were observed for 8 tumor necrosis factor (TNF)-receptors (TNF-R1, -R2, -R3, -R4, -R6B, -R7, -R19L, and -R27), key mediators of inflammatory and apoptotic pathways.
5 context sentences(design, population, supporting numbers)
Summary · context
After 6 months, 14 JKP proteins increased in the insulin glargine group and decreased in the dulaglutide group with statistically significant between-group differences.
Summary · context
In the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine.
Summary · context
This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk.
Summary · context
Plasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform.
Summary · context
Changes in circulating JKP protein concentrations from baseline to 6 months were determined.
Show in the study text Report a problemFND-4173275402
02HumanNon-randomized trialMechanism
In participants with T2D and CKD, TNF-R2 decreased with dulaglutide and increased with insulin glargine, with a significant treatment difference.
In plain wordsIn patients with diabetes and kidney disease, TNF-R2 fell with dulaglutide and rose with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTNF-R2
Study
n = 249
Comparator
Insulin glargine
Outcome group
Inflammation markers · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
The most significant differences were observed for 8 tumor necrosis factor (TNF)-receptors (TNF-R1, -R2, -R3, -R4, -R6B, -R7, -R19L, and -R27), key mediators of inflammatory and apoptotic pathways.
5 context sentences(design, population, supporting numbers)
Summary · context
After 6 months, 14 JKP proteins increased in the insulin glargine group and decreased in the dulaglutide group with statistically significant between-group differences.
Summary · context
In the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine.
Summary · context
This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk.
Summary · context
Plasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform.
Summary · context
Changes in circulating JKP protein concentrations from baseline to 6 months were determined.
Show in the study text Report a problemFND-4173275403
03HumanNon-randomized trialMechanism
In participants with T2D and CKD, TNF-R3 decreased with dulaglutide and increased with insulin glargine, with a significant treatment difference.
In plain wordsIn patients with diabetes and kidney disease, TNF-R3 fell with dulaglutide and rose with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTNF-R3
Study
n = 249
Comparator
Insulin glargine
Outcome group
Inflammation markers · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
The most significant differences were observed for 8 tumor necrosis factor (TNF)-receptors (TNF-R1, -R2, -R3, -R4, -R6B, -R7, -R19L, and -R27), key mediators of inflammatory and apoptotic pathways.
5 context sentences(design, population, supporting numbers)
Summary · context
After 6 months, 14 JKP proteins increased in the insulin glargine group and decreased in the dulaglutide group with statistically significant between-group differences.
Summary · context
In the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine.
Summary · context
This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk.
Summary · context
Plasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform.
Summary · context
Changes in circulating JKP protein concentrations from baseline to 6 months were determined.
Show in the study text Report a problemFND-4173275404
04HumanNon-randomized trialMechanism
In participants with T2D and CKD, TNF-R4 decreased with dulaglutide and increased with insulin glargine, with a significant treatment difference.
In plain wordsIn patients with diabetes and kidney disease, TNF-R4 fell with dulaglutide and rose with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTNF-R4
Study
n = 249
Comparator
Insulin glargine
Outcome group
Inflammation markers · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
The most significant differences were observed for 8 tumor necrosis factor (TNF)-receptors (TNF-R1, -R2, -R3, -R4, -R6B, -R7, -R19L, and -R27), key mediators of inflammatory and apoptotic pathways.
5 context sentences(design, population, supporting numbers)
Summary · context
After 6 months, 14 JKP proteins increased in the insulin glargine group and decreased in the dulaglutide group with statistically significant between-group differences.
Summary · context
In the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine.
Summary · context
This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk.
Summary · context
Plasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform.
Summary · context
Changes in circulating JKP protein concentrations from baseline to 6 months were determined.
Show in the study text Report a problemFND-4173275405
05HumanNon-randomized trialMechanism
In participants with T2D and CKD, TNF-R6B decreased with dulaglutide and increased with insulin glargine, with a significant treatment difference.
In plain wordsIn patients with diabetes and kidney disease, TNF-R6B fell with dulaglutide and rose with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTNF-R6B
Study
n = 249
Comparator
Insulin glargine
Outcome group
Inflammation markers · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
The most significant differences were observed for 8 tumor necrosis factor (TNF)-receptors (TNF-R1, -R2, -R3, -R4, -R6B, -R7, -R19L, and -R27), key mediators of inflammatory and apoptotic pathways.
5 context sentences(design, population, supporting numbers)
Summary · context
After 6 months, 14 JKP proteins increased in the insulin glargine group and decreased in the dulaglutide group with statistically significant between-group differences.
Summary · context
In the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine.
Summary · context
This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk.
Summary · context
Plasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform.
Summary · context
Changes in circulating JKP protein concentrations from baseline to 6 months were determined.
Show in the study text Report a problemFND-4173275406
06HumanNon-randomized trialMechanism
In participants with T2D and CKD, TNF-R7 decreased with dulaglutide and increased with insulin glargine, with a significant treatment difference.
In plain wordsIn patients with diabetes and kidney disease, TNF-R7 fell with dulaglutide and rose with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTNF-R7
Study
n = 249
Comparator
Insulin glargine
Outcome group
Inflammation markers · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
The most significant differences were observed for 8 tumor necrosis factor (TNF)-receptors (TNF-R1, -R2, -R3, -R4, -R6B, -R7, -R19L, and -R27), key mediators of inflammatory and apoptotic pathways.
5 context sentences(design, population, supporting numbers)
Summary · context
After 6 months, 14 JKP proteins increased in the insulin glargine group and decreased in the dulaglutide group with statistically significant between-group differences.
Summary · context
In the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine.
Summary · context
This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk.
Summary · context
Plasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform.
Summary · context
Changes in circulating JKP protein concentrations from baseline to 6 months were determined.
Show in the study text Report a problemFND-4173275407
07HumanNon-randomized trialMechanism
In participants with T2D and CKD, TNF-R19L decreased with dulaglutide and increased with insulin glargine, with a significant treatment difference.
In plain wordsIn patients with diabetes and kidney disease, TNF-R19L fell with dulaglutide and rose with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTNF-R19L
Study
n = 249
Comparator
Insulin glargine
Outcome group
Inflammation markers · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
The most significant differences were observed for 8 tumor necrosis factor (TNF)-receptors (TNF-R1, -R2, -R3, -R4, -R6B, -R7, -R19L, and -R27), key mediators of inflammatory and apoptotic pathways.
5 context sentences(design, population, supporting numbers)
Summary · context
After 6 months, 14 JKP proteins increased in the insulin glargine group and decreased in the dulaglutide group with statistically significant between-group differences.
Summary · context
In the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine.
Summary · context
This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk.
Summary · context
Plasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform.
Summary · context
Changes in circulating JKP protein concentrations from baseline to 6 months were determined.
Show in the study text Report a problemFND-4173275408
08HumanNon-randomized trialMechanism
In participants with T2D and CKD, TNF-R27 decreased with dulaglutide and increased with insulin glargine, with a significant treatment difference.
In plain wordsIn patients with diabetes and kidney disease, TNF-R27 fell with dulaglutide and rose with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseTNF-R27
Study
n = 249
Comparator
Insulin glargine
Outcome group
Inflammation markers · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
The most significant differences were observed for 8 tumor necrosis factor (TNF)-receptors (TNF-R1, -R2, -R3, -R4, -R6B, -R7, -R19L, and -R27), key mediators of inflammatory and apoptotic pathways.
5 context sentences(design, population, supporting numbers)
Summary · context
After 6 months, 14 JKP proteins increased in the insulin glargine group and decreased in the dulaglutide group with statistically significant between-group differences.
Summary · context
In the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine.
Summary · context
This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk.
Summary · context
Plasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform.
Summary · context
Changes in circulating JKP protein concentrations from baseline to 6 months were determined.
Show in the study text Report a problemFND-4173275409
09HumanNon-randomized trialMechanism
In participants with T2D and CKD, CD160 decreased with dulaglutide and increased with insulin glargine, with a significant treatment difference.
In plain wordsIn patients with diabetes and kidney disease, CD160 fell with dulaglutide and rose with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseCD160
Study
n = 249
Comparator
Insulin glargine
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
In addition, CD160, WFDC2, DLL1, LAYN, SYND1, and EPHA2 were significantly different between treatments, although to a lesser degree, and 7 other proteins remained unaffected.
5 context sentences(design, population, supporting numbers)
Summary · context
After 6 months, 14 JKP proteins increased in the insulin glargine group and decreased in the dulaglutide group with statistically significant between-group differences.
Summary · context
In the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine.
Summary · context
This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk.
Summary · context
Plasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform.
Summary · context
Changes in circulating JKP protein concentrations from baseline to 6 months were determined.
Show in the study text Report a problemFND-4173275410
10HumanNon-randomized trialMechanism
In participants with T2D and CKD, WFDC2 decreased with dulaglutide and increased with insulin glargine, with a significant treatment difference.
In plain wordsIn patients with diabetes and kidney disease, WFDC2 fell with dulaglutide and rose with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseWFDC2
Study
n = 249
Comparator
Insulin glargine
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
In addition, CD160, WFDC2, DLL1, LAYN, SYND1, and EPHA2 were significantly different between treatments, although to a lesser degree, and 7 other proteins remained unaffected.
5 context sentences(design, population, supporting numbers)
Summary · context
After 6 months, 14 JKP proteins increased in the insulin glargine group and decreased in the dulaglutide group with statistically significant between-group differences.
Summary · context
In the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine.
Summary · context
This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk.
Summary · context
Plasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform.
Summary · context
Changes in circulating JKP protein concentrations from baseline to 6 months were determined.
Show in the study text Report a problemFND-4173275411
11HumanNon-randomized trialMechanism
In participants with T2D and CKD, DLL1 decreased with dulaglutide and increased with insulin glargine, with a significant treatment difference.
In plain wordsIn patients with diabetes and kidney disease, DLL1 fell with dulaglutide and rose with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseDLL1
Study
n = 249
Comparator
Insulin glargine
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
In addition, CD160, WFDC2, DLL1, LAYN, SYND1, and EPHA2 were significantly different between treatments, although to a lesser degree, and 7 other proteins remained unaffected.
5 context sentences(design, population, supporting numbers)
Summary · context
After 6 months, 14 JKP proteins increased in the insulin glargine group and decreased in the dulaglutide group with statistically significant between-group differences.
Summary · context
In the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine.
Summary · context
This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk.
Summary · context
Plasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform.
Summary · context
Changes in circulating JKP protein concentrations from baseline to 6 months were determined.
Show in the study text Report a problemFND-4173275412
12HumanNon-randomized trialMechanism
In participants with T2D and CKD, LAYN decreased with dulaglutide and increased with insulin glargine, with a significant treatment difference.
In plain wordsIn patients with diabetes and kidney disease, LAYN fell with dulaglutide and rose with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseLAYN
Study
n = 249
Comparator
Insulin glargine
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
In addition, CD160, WFDC2, DLL1, LAYN, SYND1, and EPHA2 were significantly different between treatments, although to a lesser degree, and 7 other proteins remained unaffected.
5 context sentences(design, population, supporting numbers)
Summary · context
After 6 months, 14 JKP proteins increased in the insulin glargine group and decreased in the dulaglutide group with statistically significant between-group differences.
Summary · context
In the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine.
Summary · context
This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk.
Summary · context
Plasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform.
Summary · context
Changes in circulating JKP protein concentrations from baseline to 6 months were determined.
Show in the study text Report a problemFND-4173275413
13HumanNon-randomized trialMechanism
In participants with T2D and CKD, SYND1 decreased with dulaglutide and increased with insulin glargine, with a significant treatment difference.
In plain wordsIn patients with diabetes and kidney disease, SYND1 fell with dulaglutide and rose with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseSYND1
Study
n = 249
Comparator
Insulin glargine
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
In addition, CD160, WFDC2, DLL1, LAYN, SYND1, and EPHA2 were significantly different between treatments, although to a lesser degree, and 7 other proteins remained unaffected.
5 context sentences(design, population, supporting numbers)
Summary · context
After 6 months, 14 JKP proteins increased in the insulin glargine group and decreased in the dulaglutide group with statistically significant between-group differences.
Summary · context
In the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine.
Summary · context
This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk.
Summary · context
Plasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform.
Summary · context
Changes in circulating JKP protein concentrations from baseline to 6 months were determined.
Show in the study text Report a problemFND-4173275414
14HumanNon-randomized trialMechanism
In participants with T2D and CKD, EPHA2 decreased with dulaglutide and increased with insulin glargine, with a significant treatment difference.
In plain wordsIn patients with diabetes and kidney disease, EPHA2 fell with dulaglutide and rose with insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseEPHA2
Study
n = 249
Comparator
Insulin glargine
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
In addition, CD160, WFDC2, DLL1, LAYN, SYND1, and EPHA2 were significantly different between treatments, although to a lesser degree, and 7 other proteins remained unaffected.
5 context sentences(design, population, supporting numbers)
Summary · context
After 6 months, 14 JKP proteins increased in the insulin glargine group and decreased in the dulaglutide group with statistically significant between-group differences.
Summary · context
In the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine.
Summary · context
This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk.
Summary · context
Plasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform.
Summary · context
Changes in circulating JKP protein concentrations from baseline to 6 months were determined.
Show in the study text Report a problemFND-4173275415
15HumanNon-randomized trialMechanism
In participants with T2D and CKD, seven other JKP proteins remained unaffected by the dulaglutide versus insulin glargine comparison.
In plain wordsIn patients with diabetes and kidney disease, seven other kidney-panel proteins showed no effect from dulaglutide versus insulin glargine.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeOther JKP proteins
Study
n = 249
Comparator
Insulin glargine
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
In addition, CD160, WFDC2, DLL1, LAYN, SYND1, and EPHA2 were significantly different between treatments, although to a lesser degree, and 7 other proteins remained unaffected.
4 context sentences(design, population, supporting numbers)
Summary · context
In the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine.
Summary · context
This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk.
Summary · context
Plasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform.
Summary · context
Changes in circulating JKP protein concentrations from baseline to 6 months were determined.
Show in the study text Report a problemFND-4173275416
16HumanNon-randomized trialMechanism
In participants with T2D and CKD, KIM1 declined in both dulaglutide and insulin glargine groups without significant between-group differences.
In plain wordsIn patients with diabetes and kidney disease, KIM1 fell with both dulaglutide and insulin glargine, without a significant treatment difference.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeKIM1 treatment difference
Study
n = 249
Comparator
Insulin glargine
Outcome group
Kidney function · Kidney and urinary
Studied dose
Dose not stated · 6 monthsAs given in this study (human).
Source sentences
Summary
Kidney injury molecule 1 (KIM1), a marker of proximal tubule stress, declined in both groups without significant differences.
4 context sentences(design, population, supporting numbers)
Summary · context
In the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine.
Summary · context
This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk.
Summary · context
Plasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform.
Summary · context
Changes in circulating JKP protein concentrations from baseline to 6 months were determined.
Show in the study text Report a problemFND-4173275417

Studies that did not test the peptide alone1

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

17HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyMechanism
Dulaglutide treatment effects on JKP proteins were stronger with lower baseline eGFR or higher albuminuria, HbA1c or BMI.
In plain wordsIn patients with diabetes and kidney disease, dulaglutide's protein effects were larger with lower kidney function or higher urine albumin, HbA1c or BMI.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableBaseline modifiers of protein response
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
Treatment effects were more pronounced in participants with lower baseline estimated glomerular filtration rate or higher baseline urinary albumin-to-creatinine ratio, hemoglobin A1c, or body mass index.
4 context sentences(design, population, supporting numbers)
Summary · context
In the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine.
Summary · context
This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk.
Summary · context
Plasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform.
Summary · context
Changes in circulating JKP protein concentrations from baseline to 6 months were determined.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-4173275418

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.